These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20003697)

  • 1. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis.
    Wang JY; Wang JT; Tsai TH; Hsu CL; Yu CJ; Hsueh PR; Lee LN; Yang PC
    Int J Tuberc Lung Dis; 2010 Jan; 14(1):65-71. PubMed ID: 20003697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
    Koh WJ; Lee SH; Kang YA; Lee CH; Choi JC; Lee JH; Jang SH; Yoo KH; Jung KH; Kim KU; Choi SB; Ryu YJ; Chan Kim K; Um S; Kwon YS; Kim YH; Choi WI; Jeon K; Hwang YI; Kim SJ; Lee YS; Heo EY; Lee J; Ki YW; Shim TS; Yim JJ
    Am J Respir Crit Care Med; 2013 Oct; 188(7):858-64. PubMed ID: 23927582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
    Burman WJ; Goldberg S; Johnson JL; Muzanye G; Engle M; Mosher AW; Choudhri S; Daley CL; Munsiff SS; Zhao Z; Vernon A; Chaisson RE
    Am J Respir Crit Care Med; 2006 Aug; 174(3):331-8. PubMed ID: 16675781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
    Wang JY; Lee LN; Yu CJ; Chien YJ; Yang PC;
    Respirology; 2009 Sep; 14(7):1012-9. PubMed ID: 19659516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
    Dorman SE; Johnson JL; Goldberg S; Muzanye G; Padayatchi N; Bozeman L; Heilig CM; Bernardo J; Choudhri S; Grosset JH; Guy E; Guyadeen P; Leus MC; Maltas G; Menzies D; Nuermberger EL; Villarino M; Vernon A; Chaisson RE;
    Am J Respir Crit Care Med; 2009 Aug; 180(3):273-80. PubMed ID: 19406981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
    Velayutham BV; Allaudeen IS; Sivaramakrishnan GN; Perumal V; Nair D; Chinnaiyan P; Paramasivam PK; Dhanaraj B; Santhanakrishnan RK; Navaneethapandian GP; Marimuthu MK; Kumar V; Kandasamy C; Dharuman K; Elangovan T; Narasimhan M; Rathinam S; Vadivelu G; Rathinam P; Chockalingam C; Jayabal L; Swaminathan S; Shaheed JM
    Clin Infect Dis; 2014 Nov; 59(10):e142-9. PubMed ID: 25028463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
    Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it.
    Parikh R; Nataraj G; Kanade S; Khatri V; Mehta P
    J Assoc Physicians India; 2012 Aug; 60():22-6. PubMed ID: 23405517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
    Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD
    J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
    Jiang RH; Xu HB; Li L
    Int J Antimicrob Agents; 2013 Jul; 42(1):36-41. PubMed ID: 23582696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.
    Kurbatova EV; Gammino VM; Bayona J; Becerra MC; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Taylor A; Viiklepp P; Zignol M; Cegielski JP
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1335-43. PubMed ID: 23107633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Mycobacterium tuberculosis lineage and time to sputum culture conversion.
    Click ES; Winston CA; Oeltmann JE; Moonan PK; Mac Kenzie WR
    Int J Tuberc Lung Dis; 2013 Jul; 17(7):878-84. PubMed ID: 23743308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis.
    Fouad M; Gallagher JC
    Ann Pharmacother; 2011 Nov; 45(11):1439-44. PubMed ID: 21990937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
    N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diarylquinoline TMC207 for multidrug-resistant tuberculosis.
    Diacon AH; Pym A; Grobusch M; Patientia R; Rustomjee R; Page-Shipp L; Pistorius C; Krause R; Bogoshi M; Churchyard G; Venter A; Allen J; Palomino JC; De Marez T; van Heeswijk RP; Lounis N; Meyvisch P; Verbeeck J; Parys W; de Beule K; Andries K; Mc Neeley DF
    N Engl J Med; 2009 Jun; 360(23):2397-405. PubMed ID: 19494215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yield of continued monthly sputum evaluation among tuberculosis patients after culture conversion.
    Sundaram V; Fujiwara PI; Driver CR; Osahan SS; Munsiff SS
    Int J Tuberc Lung Dis; 2002 Mar; 6(3):238-45. PubMed ID: 11934142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.